How I Treat Myelofibrosis Patients Who Have “Failed” Ruxolitinib
Upon viewing this session, you will be able to identify the current role of ruxolitinib in myelofibrosis, and which patients have “failed” ruxolitinib, determine role of stem cell transplant as salvage in those who have failed ruxolitinib in myelofibrosis, identify whether combination therapy, which includes, ruxolitinib, should be considered and in which patients, and recognize potential role of new JAK inhibitors and alternative pathway inhibitors for managing myelofibrosis.
Ruben A. Mesa, MD, Mayo Clinic
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members